<DOC>
	<DOCNO>NCT01524497</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , parallel-group , placebo-controlled study evaluate efficacy safety trazodone hydrochloride prolonged-release tablet treatment depression Chinese population .</brief_summary>
	<brief_title>A Clinical Study Trazodone Hydrochloride Prolonged-Release Tablets Treatment Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Trazodone</mesh_term>
	<criteria>1 . Age 18 65 , male female , outpatient inpatient ; 2 . Single episode recurrent depression accord DSMIV ( Version 4 ) criterion ; 3 . Scores &gt; 18 17item HAMD screen baseline visit decrease exceed 20 % two visit ; 4 . Symptoms depression least 1 month ; 5 . Patients dependents/guardians provide sign informed consent form . 1 . Serious suicide attempt ( â‰¥ 3 item 3 'Suicide ' HAMD ) ; 2 . Depressive episode , psychotic symptom ; 3 . Refractory depression ; 4 . Depressive episode secondary mental physical disorder ; 5 . Bipolar disorder ; 6 . Significant reduction body weight malnutrition induce major depression ; 7 . Serious unstable heart , hepatic , renal , endocrine hematologic disease malignant tumor ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>lose interest feeling guilt</keyword>
	<keyword>poor concentration</keyword>
	<keyword>loss appetite</keyword>
	<keyword>suicide</keyword>
</DOC>